- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Diagonal Bio AB's announces last day of trading in BTU and first day of trading in warrants of series TO 2 | 2 | Cision News | ||
| Di | Diagonal Bio AB resolves on a directed issue of units to all external underwriters | 4 | Cision News | ||
| 12.02. | DIAGONAL BIO AB: Diagonal Bio's CEO Karin Wehlin increases ownership | 1 | Cision News | ||
| 07.02. | Diagonal Bio AB: Diagonal Bio AB's rights issue of units oversubscribed | 220 | GlobeNewswire (Europe) | The subscription period in Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units of initially approximately SEK 6.0 million ended on 6 February 2025 (the "Rights Issue"). The Rights... ► Artikel lesen | |
| 05.02. | DIAGONAL BIO AB: Stall Goop conducts pilot test of LAMPlify® | 1 | Cision News | ||
| 29.01. | Diagonal Bio AB: Diagonal Bio announces positive pilot test results and secures order from StallZet | 38 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") announces an order valued at approximately SEK 150,000 from Daniel Redén, a renowned horse trainer at StallZet. The order comes as a result of... ► Artikel lesen | |
| 23.01. | The subscription period of Diagonal Bio AB's rights issue of units commences today | 1 | Cision News | ||
| 22.01. | Diagonal Bio AB: Diagonal Bio AB publishes investment memorandum prior to upcoming rights issue of units | 121 | GlobeNewswire (Europe) | The subscription period of Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units, which was resolved on 23 December 2024 by the Board of Directors together with the resolution on... ► Artikel lesen | |
| DIAGONAL BIO Aktie jetzt für 0€ handeln | |||||
| 17.01. | DIAGONAL BIO AB: Nomination Committee change in Diagonal Bio (publ.) | 2 | Cision News | ||
| 17.01. | Bulletin from the Extraordinary General Meeting of Diagonal Bio AB on 17 January 2025 | 2 | Cision News | ||
| 17.01. | XFRA CAPITAL ADJUSTMENT INFORMATION - 17.01.2025 | 174 | Xetra Newsboard | Das Instrument 2DV0 FR001400SVN0 DRONE VOLT SACA EO 1 EQUITY wird ex Kapitalmassnahme gehandelt am 17.01.2025 The instrument 2DV0 FR001400SVN0 DRONE VOLT SACA EO 1 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| 14.01. | DIAGONAL BIO AB: Diagonal Bio expands its testing panel for horses with EHV-5 detection | 1 | Cision News | ||
| 23.12.24 | DIAGONAL BIO AB: Diagonal Bio enters into a strategic partnership with Daniel Redén at StallZet to enhance commercialisation plans | 3 | Cision News | ||
| 22.11.24 | DIAGONAL BIO AB: Renowned horse race jockey and trainer conducts pilot test of LAMPlify® | 1 | Cision News | ||
| 18.11.24 | DIAGONAL BIO AB: Nomination Committee appointed for Diagonal Bio | 1 | Cision News | ||
| 13.11.24 | DIAGONAL BIO AB: Diagonal Bio announces pilot test with LAMPlify® at Kolgjini Stables | 1 | Cision News | ||
| 11.11.24 | Nasdaq Stockholm AB: Diagonal Bio AB receives observation status | 230 | GlobeNewswire | Today, on November 11, 2024, Diagonal Bio AB (the "Company") disclosed a press
release with information on the Company's financial situation.
The rules of Nasdaq First North Growth Market state that... ► Artikel lesen | |
| 11.11.24 | DIAGONAL BIO AB: Diagonal Bio announces that it is exploring financing options | 3 | Cision News | ||
| 31.10.24 | DIAGONAL BIO AB: Diagonal announces first pilot test at a stud with LAMPlify® | 4 | Cision News | ||
| 25.10.24 | DIAGONAL BIO AB: Diagonal Bio announces pilot test of LAMPlify® at Norwegian University of Life Sciences | 5 | Cision News |
Seite:
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 11,645 | +0,04 % | Intellia Therapeutics, Inc. - 8-K, Current Report | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,494 | +1,83 % | Where Pacific Biosciences Stands With Analysts | ||
| CENTOGENE | 0,120 | -36,84 % | Centogene NV: CENTOGENE Announces Voting Results of Extraordinary General Meeting | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,865 | -1,74 % | atai Acquires Psilera's DMT Patent Portfolio | ||
| BIOMERIEUX | 112,00 | -0,27 % | bioMérieux S.A. (OTCMKTS:BMXMF) Sees Large Drop in Short Interest | ||
| CYCLACEL | 0,320 | 0,00 % | Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs | BERKELEY HEIGHTS, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 0,177 | +6,63 % | Kia India Begins Production of Syros SUV | Kia Syros SUV records 10,258 pre-orders, continuing impressive momentum following world premiere in December 2024New family-focused SUV specifically designed for customers in IndiaGroundbreaking... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,390 | +6,11 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
| GENUS | 20,800 | -1,89 % | Genus Sees H1 Adj. Profit Before Tax Ahead Of Expectations | LONDON (dpa-AFX) - Genus Plc (GNS.L), a biotechnology firm focused on animal genetics, said on Wednesday that it has recorded a strong performance for the first half and expects its earnings... ► Artikel lesen | |
| ANAPTYSBIO | 17,300 | -2,81 % | ANAPTYSBIO, INC - 8-K, Current Report | ||
| ABIONYX PHARMA | 1,242 | +5,43 % | ABIONYX Pharma, winner of the France 2030 Plan's "i-Démo" call for projects, awarded €8.7 million from the French government to fight against Sepsis, the 3rd leading cause of death worldwide | ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant... ► Artikel lesen | |
| MEIRAGTX | 6,800 | -2,16 % | MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy | As disclosed in the paper, 4 out of 4 young children with the AIPL1-related retinal dystrophy, LCA4, benefited substantially from unilateral subretinal administration of rAAV8.hRKp.AIPL1 with improved... ► Artikel lesen | |
| METABOLIC EXPLORER | 0,095 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 09.10.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 09.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 09.10.2024ISIN NameAU0000064966 VIRG.MON.... ► Artikel lesen | |
| AKESO | 8,550 | +2,40 % | Akeso, Inc.: Akeso Enrolled First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer | HONG KONG, Feb. 20, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,144 | -0,83 % | Isofol Medical AB: Isofol Medical AB (publ) publishes year-end report, January - December 2024 | GOTHENBURG, Sweden, February 19, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's year-end report for January - December 2024 is now available on the company's... ► Artikel lesen |
Das Unternehmen DIAGONAL BIO AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,002 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAGONAL BIO AB finden Sie auf Wallstreet Online.
